Literature DB >> 22649210

Comparative effectiveness research: what is it and why do we need it in nephrology?

Tara I Chang, Wolfgang C Winkelmayer.   

Abstract

The USA leads other industrialized countries in health care spending but lags behind in terms of health outcomes. There has been growing interest in comparative effectiveness research (CER) as a means to identify best practices to create a more efficient and effective health care system. Two key concepts of CER are that it should (i) compare two or more alternative tests, therapies or procedures and (ii) be conducted in persons, clinical settings and conditions that are representative of the real world. The goal of CER is to provide evidence for clinicians, patients, policy makers and others to make informed decisions that will ultimately improve the overall health of specific subgroups and of the population as a whole. In this narrative review, we first describe the strengths and limitations of various types of studies that constitute CER, including randomized clinical trials, observational studies and systematic reviews, providing examples from the nephrology literature. Because of the concerns regarding confounding in observational CER, we also provide an overview of methods to reduce confounding in these types of studies. Finally, we will discuss why CER pertaining to kidney disease care needs to be a top priority in order to move our field from a largely opinion-based specialty to an evidence-based specialty.

Entities:  

Mesh:

Year:  2012        PMID: 22649210     DOI: 10.1093/ndt/gfs154

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  A comparative study of the risk profile of hemodialysis patients in a for profit network and in two regional registries of the Italian Society of Nephrology.

Authors:  Maurizio Postorino; Claudia Amato; Elena Mancini; Paola Carioni; Graziella D'Arrigo; Attilio Di Benedetto; Fabrizio Cerino; Carmela Marino; Antonio Vilasi; Giovanni Tripepi; Stefano Stuard; Giovanbattista Capasso; Antonio Santoro; Carmine Zoccali
Journal:  J Nephrol       Date:  2017-02-16       Impact factor: 3.902

2.  Cardiovascular disease: Is CABG really better than PCI in dialysis patients?

Authors:  Christoph Wanner; Kitty J Jager
Journal:  Nat Rev Nephrol       Date:  2013-03-12       Impact factor: 28.314

3.  Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.

Authors:  Jenny I Shen; Maria E Montez-Rath; Colin R Lenihan; Mintu P Turakhia; Tara I Chang; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2015-07-07       Impact factor: 8.860

4.  Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.

Authors:  Emma Gray; David J Pasta; Suzanne Norris; Aisling O'Leary
Journal:  BMC Health Serv Res       Date:  2017-04-19       Impact factor: 2.655

5.  Three-year clinical experience with magnetic sphincter augmentation and laparoscopic fundoplication.

Authors:  Luigi Bonavina; Thomas Horbach; Sebastian F Schoppmann; Janet DeMarchi
Journal:  Surg Endosc       Date:  2020-07-16       Impact factor: 4.584

Review 6.  Comparative effectiveness research and its utility in In-clinic practice.

Authors:  Amit Dang; Kirandeep Kaur
Journal:  Perspect Clin Res       Date:  2016 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.